By integrating phase separation biology with metabolic and immune checkpoints, the work supports a condensate-linked regulatory axis and motivates hypothesis-driven strategies: stabilizing or mimicking TIA1-dependent glycolytic restraint should be explored cautiously to potentially enhance intravesical BCG and other immunotherapies in bladder cancer pending further validation. This evidence concerns the gene TIA1 and urinary bladder carcinoma.